TABLE 2.
Computed tomography tumor volume measurements before and after DEB‐TACE for dogs with HC as risk factors for survival
| CT tumor size measurement | Median (range) | P value | Median (range) | P value | Median (range) | P value |
|---|---|---|---|---|---|---|
| Before DEB‐TACE | After DEB‐TACE | Percent change following DEB‐TACE | ||||
| Volume (mL) | 281 (48.7‐1580) | .13 | 258 (45.0‐1301) | .15 | −13% (−56% to 77%) | .39 |
| Volume/body weight (mL/kg) | 30.0 (5.70‐87.3) | .03 * | 25.7 (3.90‐117) | .02 * | ||
| Ellipsoid tumor response classification | Complete response | 0 (0%) | N/A | |||
| Partial response | 3 (23%) | |||||
| Stable disease | 8 (62%) | |||||
| Progressive disease | 2 (15%) | |||||
| Change in size | Decreased | 10 (77%) | .12 | |||
| Increased | 3 (23%) | |||||
Abbreviations: DEB‐TACE, drug‐eluting bead transarterial chemoembolization; HC, hepatic carcinoma.
*
P < .05.